Treating prostate cancer with anti-ErbB2 antibodies

Details Treating prostate cancer with anti-ErbB2 antibodies Treating prostate cancer with anti-ErbB2 antibodies

2006-05-09

2006-05-09

Siew, Jeffrey (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S135100, C424S136100, C424S138100, C424S141100, C424S142100, C424S172100, C424S174100, C424S800000, C424S801000

Reexamination Certificate

active

07041292

ABSTRACT:
The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.

REFERENCES:
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5288477 (1994-02-01), Bacus
patent: 5359046 (1994-10-01), Capon et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5464751 (1995-11-01), Greene et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5571894 (1996-11-01), Wels et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5604107 (1997-02-01), Carney et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5663144 (1997-09-01), Greene et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5747261 (1998-05-01), King et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5783404 (1998-07-01), Koski
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5804396 (1998-09-01), Plowman
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5834229 (1998-11-01), Vandlen et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5837523 (1998-11-01), Greene et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5846749 (1998-12-01), Slamon et al.
patent: 5856089 (1999-01-01), Wang et al.
patent: 5856110 (1999-01-01), Vandlen et al.
patent: 5859206 (1999-01-01), Vandlen et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5882864 (1999-03-01), An et al.
patent: 5908835 (1999-06-01), Bissery
patent: 5910486 (1999-06-01), Curiel et al.
patent: 5922845 (1999-07-01), Deo et al.
patent: 5925519 (1999-07-01), Jensen et al.
patent: 5939531 (1999-08-01), Wels et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 5985553 (1999-11-01), King et al.
patent: 5994071 (1999-11-01), Ross et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6028059 (2000-02-01), Curiel et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6096873 (2000-08-01), Schaefer et al.
patent: 6123939 (2000-09-01), Shawver et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6270765 (2001-08-01), Deo et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6358682 (2002-03-01), Jaffee et al.
patent: 6395272 (2002-05-01), Deo et al.
patent: 6403630 (2002-06-01), Dannenberg et al.
patent: 6417168 (2002-07-01), Greene et al.
patent: 6458356 (2002-10-01), Arakawa et al.
patent: 6512097 (2003-01-01), Marks et al.
patent: 6582919 (2003-06-01), Danenberg
patent: 2002/0076695 (2002-06-01), Ross et al.
patent: 2002/0155527 (2002-10-01), Stuart et al.
patent: 2003/0211530 (2003-11-01), Danenberg
patent: 332865 (1989-09-01), None
patent: 599274 (1994-06-01), None
patent: 0616812 (1994-09-01), None
patent: 656367 (1995-06-01), None
patent: 412116 (1995-11-01), None
patent: 494135 (1996-04-01), None
patent: 502812 (1996-08-01), None
patent: 711565 (1998-08-01), None
patent: 554441 (1999-01-01), None
patent: 1006194 (2000-06-01), None
patent: 444181 (2001-10-01), None
patent: 3-240498 (1991-10-01), None
patent: 5-117165 (1993-05-01), None
patent: 5-170667 (1993-07-01), None
patent: 5-213775 (1993-08-01), None
patent: 5-317084 (1993-12-01), None
patent: 95006982 (1995-01-01), None
patent: 7-59588 (1995-03-01), None
patent: 2761543 (1998-06-01), None
patent: 2895105 (1999-05-01), None
patent: WO 87/07646 (1987-12-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 89/10412 (1989-11-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO 91/05264 (1991-04-01), None
patent: WO 92/10573 (1992-06-01), None
patent: WO 92/20798 (1992-11-01), None
patent: WO 93/03781 (1993-03-01), None
patent: WO 93/12220 (1993-06-01), None
patent: WO 93/16185 (1993-08-01), None
patent: WO 93/21232 (1993-10-01), None
patent: WO 93/21319 (1993-10-01), None
patent: WO 94/00136 (1994-01-01), None
patent: WO 94/22478 (1994-10-01), None
patent: WO 94/28127 (1994-12-01), None
patent: WO 95/16051 (1995-06-01), None
patent: WO 95/17507 (1995-06-01), None
patent: WO 95/28485 (1995-10-01), None
patent: WO 96/07321 (1996-03-01), None
patent: WO 96/16673 (1996-06-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 96/40789 (1996-12-01), None
patent: WO 97/00271 (1997-01-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO 97/20858 (1997-06-01), None
patent: WO 97/27848 (1997-08-01), None
patent: WO 97/35885 (1997-10-01), None
patent: WO 97/38731 (1997-10-01), None
patent: WO 98/02463 (1998-01-01), None
patent: WO 98/02540 (1998-01-01), None
patent: WO 98/02541 (1998-01-01), None
patent: WO 98/16628 (1998-04-01), None
patent: WO 98/17797 (1998-04-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO 98/33914 (1998-08-01), None
patent: WO 98/45479 (1998-10-01), None
patent: WO 99/31140 (1999-06-01), None
patent: WO 99/39729 (1999-08-01), None
patent: WO 99/55367 (1999-11-01), None
patent: WO 00/61145 (2000-10-01), None
patent: WO 00/61185 (2000-10-01), None
patent: WO 00/69460 (2000-11-01), None
patent: WO 00/78347 (2000-12-01), None
patent: WO 01/00238 (2001-01-01), None
patent: WO 01/00244 (2001-01-01), None
patent: WO 01/05425 (2001-02-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO 01/15730 (2001-03-01), None
patent: WO 01/20033 (2001-03-01), None
patent: WO 01/21192 (2001-03-01), None
patent: WO 01/32255 (2001-05-01), None
Zhi, Dissertation Abstracts, vol. 55, No. 11, p. 4738-B, May 1995.
Shepard et al., Journal of Clinical Immunology, vol. 11, No. 9, pp. 117-126, 1991.
Fendly et al., Cancer Research, vol. 50, pp. 1550-1558, Mar. 1, 1990.
Baselga et al., Journal of Clinical Oncology, vol. 14, No. 3, pp. 737-744, Mar. 1996 (Baselga II).
Murphy et al., The American Society Textbook of Clinical Oncology, 1995, pp. 126-127.
Xu et al., Int. J. Cancer, vol. 53, pp. 401-408, 1993.
Reese, D. et al. Proceedings of the American Association for Cancer Research, 37: p. 51, Mar. 1996; Abstract #353.
U.S. Appl. No. 09/602,802, filed Jun. 23, 2000, Sliwkowski.
Angus at al., “Differential anti-tumor effects of targeting distinct epitopes of the Her-2
eu extracellular domain in xenograft models of prostate cancer”Proceedings of the American Association for Cancer Research Annual Meeting(abstract #4570) 41:719 (Mar. 2000).
Baselga et al., “Anti-HER2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts”Proceedings of ASCO-13th Annual Meeting(Abstract #53), Dallas, TX 13:63 (Mar. 1994).
Baselga et al., “HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications”Oncology11(3 Suppl 2):43-48 (Mar. 1997).
Baselga et al., “Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents”Annals of Oncology(abstract #010) 5(Suppl. 5) (1994).
Baselga et al., “Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enchances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
eu Overexpression Human Breast Cancer Xenografts”Cancer Research58:2825-2831 (Jul. 1998).
Curnow, R., “Clinical experience with CD64-directed im

Affiliated with

Also associated with

Rating

Treating prostate cancer with anti-ErbB2 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treating prostate cancer with anti-ErbB2 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating prostate cancer with anti-ErbB2 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3548790